PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Positive gross profit growth while AGEN is negative. John Neff would see a clear operational edge over the competitor.
-1.47%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-1.47%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-1.89%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
2.63%
Positive EPS growth while AGEN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.63%
Positive diluted EPS growth while AGEN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
3.22%
Share count expansion well above AGEN's 2.32%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
3.22%
Diluted share count expanding well above AGEN's 2.32%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-50.21%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-50.21%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
91.36%
10Y OCF/share CAGR above 1.5x AGEN's 4.16%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
62.52%
5Y OCF/share CAGR above 1.5x AGEN's 38.76%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-48.56%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
94.18%
Positive 10Y CAGR while AGEN is negative. John Neff might see a substantial advantage in bottom-line trajectory.
69.28%
5Y net income/share CAGR 1.25-1.5x AGEN's 53.39%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
-24.85%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-50.75%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-32.62%
Negative 5Y equity/share growth while AGEN is at 86.04%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-67.01%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-15.55%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-7.46%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
10.75%
R&D growth drastically higher vs. AGEN's 11.66%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-21.32%
We cut SG&A while AGEN invests at 2.73%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.